相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The Role of BRCA Status on the Prognosis of Patients with Epithelial Ovarian Cancer: A Systematic Review of the Literature with a Meta-Analysis
Chaoyang Sun et al.
PLOS ONE (2014)
Minireview: Human Ovarian Cancer: Biology, Current Management, and Paths to Personalizing Therapy
Ignacio Romero et al.
ENDOCRINOLOGY (2012)
Phase II, Open-Label, Randomized, Multicenter Study Comparing the Efficacy and Safety of Olaparib, a Poly (ADP-Ribose) Polymerase Inhibitor, and Pegylated Liposomal Doxorubicin in Patients With BRCA1 or BRCA2 Mutations and Recurrent Ovarian Cancer
Stan B. Kaye et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
BRCA Mutation Frequency and Patterns of Treatment Response in BRCA Mutation-Positive Women With Ovarian Cancer: A Report From the Australian Ovarian Cancer Study Group
Kathryn Alsop et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
A high response rate to liposomal doxorubicin is seen among women with BRCA mutations treated for recurrent epithelial ovarian cancer
Sarah F. Adams et al.
GYNECOLOGIC ONCOLOGY (2011)
Personalizing Cancer Treatment in the Age of Global Genomic Analyses: PALB2 Gene Mutations and the Response to DNA Damaging Agents in Pancreatic Cancer
Maria C. Villarroel et al.
MOLECULAR CANCER THERAPEUTICS (2011)
BRCA Mutation Status and Determinant of Outcome in Women with Recurrent Epithelial Ovarian Cancer Treated with Pegylated Liposomal Doxorubicin
Tamar Safra et al.
MOLECULAR CANCER THERAPEUTICS (2011)
Drug therapy for hereditary cancers
Evgeny N. Imyanitov et al.
HEREDITARY CANCER IN CLINICAL PRACTICE (2011)
Somatic Mutations in BRCA1 and BRCA2 Could Expand the Number of Patients That Benefit From Poly (ADP Ribose) Polymerase Inhibitors in Ovarian Cancer
Bryan T. J. Hennessy et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Personalizing Therapy for Ovarian Cancer: BRCAness and Beyond
Robert C. Bast et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
M. William Audeh et al.
LANCET (2010)
Prolonged survival in a patient with BRCA2 associated metastatic pancreatic cancer after exposure to camptothecin: a case report and review of literature
Edward James et al.
ANTI-CANCER DRUGS (2009)
Premature senescence is a major response to DNA cross-linking agents in BRCA1-defective cells: implication for tailored treatments of BRCA1 mutation carriers
Manuela Santarosa et al.
MOLECULAR CANCER THERAPEUTICS (2009)
High frequency of BRCA1, but not CHEK2 or NBS1 (NBN), founder mutations in Russian ovarian cancer patients
Evgeny N. Suspitsin et al.
HEREDITARY CANCER IN CLINICAL PRACTICE (2009)
Founder mutations in early-onset, familial and bilateral breast cancer patients from Russia
Anna P. Sokolenko et al.
FAMILIAL CANCER (2007)
Hypersensitivity of Brca1-deficient MEF to the DNA interstrand crosslinking agent mitomycin C is associated with defect in homologous recombination repair and aberrant S-phase arrest
JH Yun et al.
ONCOGENE (2005)
分享论文
